MacroGenics (MGNX) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vogenx is the larger company by market cap ($259.8 million vs $226.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | VOGX |
|---|---|---|
| Share price | $3.55 | $17.49 |
| Market cap | $226.14M | $259.82M |
| 1-day change | 0.00% | +8.23% |
| YTD return | +120.50% | — |
| 1-year return | +99.44% | — |
| 5-year return | -82.02% | — |
| EPS (TTM) | $-1.70 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $38.41 |
| 52-week low | $1.29 | $12.95 |
| Distance from 52-week high | -30.12% | -54.46% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +125.35% | +214.47% |
| Average volume | 621.73K | 188.79K |
| Shares outstanding | 63.70M | 14.86M |
| Employees | 293 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
MGNX vs VOGX FAQ
Which is bigger, MacroGenics or Vogenx?
Vogenx (VOGX) is larger, with a market capitalization of $259.82M compared with $226.14M for MacroGenics (MGNX).
Are MacroGenics and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.